PRL002

Next-Generation Diabetes Drug Offers Great Growth Potential
Motley Fool
Sat, 01/10/15 - 01:11 pm
diabetes
Novo Nordisk
Perle Biosciences
PRL001
PRL002
JNJ
AstraZeneca
Bristol-Myers Squibb